Cardiff Lexington Corporation reports operating and capital-market developments for a healthcare services holding company focused on orthopedic, spine and pain-management platforms. Its current revenue is derived from Nova Ortho and Spine, which operates regional specialty and ancillary orthopedic care centers in Florida and Georgia that provide diagnostic services, surgical services, primary care evaluations, interventional pain management and specialty consultations for traumatic injury patients.
Recurring updates include financial results, patient-volume and procedure mix, facility and clinician additions, activity at Nova Ortho and Spine locations, acquisition strategy for orthopedic practices and related healthcare assets, OTC market status, reverse stock split actions, registration-statement activity and board governance changes.
Cardiff Lexington (CDIX) entered a letter of intent on September 24, 2026, for a proposed acquisition valued at up to $104 million.
The target operates a multi-location musculoskeletal healthcare platform. Proposed consideration includes $30 million in cash at closing, $10 million in unsecured notes payable two years after closing, and preferred equity that would leave the sellers owning 35% of Cardiff Lexington’s fully diluted equity. Sellers could also receive up to $12 million in common stock if the target meets specified EBITDA thresholds for 2027 through 2029.
The LOI projects a November 16, 2026, closing but does not bind the parties to complete the transaction. Closing depends on due diligence, financing, definitive agreements and other conditions. Cardiff Lexington has not obtained binding financing commitments.
Cardiff Lexington (OTCQX:CDIX) reported second quarter 2026 revenue of $2.16 million, down from $2.79 million a year earlier, with a net loss of $2.48 million versus $1.23 million. For the first half of 2026, revenue was $4.38 million compared to $5.70 million in 2025, while gross margin reached 57%.
First-half net loss widened to $5.57 million from $1.68 million, driven partly by $4.05 million in interest expense. Adjusted EBITDA was a loss of $13,740, but Adjusted EBITDA excluding non-recurring costs was positive $270,372. Cardiff Lexington highlighted working capital constraints, high-cost capital and the opening of its 12th Nova Ortho and Spine location.
Cardiff Lexington (OTCQX:CDIX) will release its financial and operating results for the second quarter ended June 30, 2026, on Wednesday, August 12, 2026, before hosting an investor conference call at 11:00 a.m. ET.
U.S. participants can join by dialing (888) 506-0062, while international participants should dial (973) 528-0011 and use access code 876877. The call and slide deck will be webcast at https://www.webcaster5.com/Webcast/Page/3131/54266, with an online archive available afterward. A telephone replay will be accessible until August 26, 2026 at (877) 481-4010 (U.S.) or (919) 882-2331 (international), using access code 54266. Cardiff Lexington describes itself as a healthcare services holding company focused on orthopedic, spine, and pain management platforms, pursuing scalable growth through acquisitions and strategic partnerships.
Cardiff Lexington (OTCQX:CDIX) announced that subsidiary Nova Ortho and Spine has added Southeastern Surgery Center in Tallahassee, Florida as its 12th surgical center. The site expands access to minimally invasive pain management and spine procedures, with plans to add open surgical procedures and deepen presence in the southeast and mid-Atlantic.
Cardiff Lexington (OTCQX:CDIX) announced that subsidiary Nova Ortho and Spine has opened a new 2,975-square-foot medical office in Stuart, Florida. The clinic, on NW Federal Highway, expands Nova’s orthopedic, spine, and musculoskeletal care network along Florida’s growing Treasure Coast, serving Martin and St. Lucie County communities exceeding 650,000 residents.
Cardiff Lexington (OTCQX:CDIX) reported first quarter 2026 results for the period ended March 31, 2026. Revenue was $2.2 million versus $2.9 million a year ago, with gross profit of $1.3 million (59.3% margin).
Operating expenses rose to $1.8 million, including $664,000 of share-based compensation. The company reported a loss from continuing operations of $511,000 and a net loss of $3.1 million, including $1.9 million of interest expense. Adjusted EBITDA was $164,000. Cash was $684,000 and total assets increased 4.1% to $30.3 million. Management highlighted expansion of Nova Ortho and Spine locations and an upgrade to the OTCQX market. A conference call is scheduled for May 19, 2026, at 11:00 a.m. Eastern Time.
Cardiff Lexington (OTCQX:CDIX) will release first quarter 2026 financial and operating results on Tuesday, May 19, 2026, before market events, and host an investor conference call at 11:00 a.m. ET.
The call offers phone dial-in, webcast with slide deck, and replay access through June 2, 2026.
Cardiff Lexington (OTCQX:CDIX) was approved to trade on the OTCQX Best Market effective April 9, 2026, continuing under symbol CDIX. The upgrade highlights enhanced transparency, governance and a step toward a potential uplisting to a national exchange.
For FY2025 the company reported $11.5M revenue (+39.5% vs 2024), $7.2M gross profit (62.5% margin), $1.1M operating income (9.5% margin) and $29.1M total assets (+21.6%). Management cites working capital constraints as the primary limit on utilization and plans capital formation to scale operations and accelerate AR conversion.
Cardiff Lexington (OTCQB: CDIX) reported full year 2025 results: revenue $11.5M (up 39.5% YoY) and gross profit $7.2M (62.5% margin). Operating income was $1.1M while net loss was $(5.5M) due largely to $6.8M interest expense. The company executed a 1-for-3 reverse split and announced a March 16, 2026 investor webcast.
Management cited higher patient volumes, a shift to higher-value surgical procedures, expanded operations in Florida and Georgia, and talent additions to support growth and a planned uplisting.
Cardiff Lexington (OTCQB: CDIX) will release its fourth quarter and full year 2025 financial and operating results and host a conference call on Monday, March 16, 2026 at 11:00 am ET.
Shareholders can join via dial-in or webcast; a slide deck and an online replay (available through March 30, 2026) will be posted on the company's Investor Relations site.